Back to Pharma Services
Wilmington PharmaTech
US-based CDMO specializing in complex chemistry, small molecules, and high-potency API manufacturing with integrated development and GMP manufacturing services from discovery through commercial supply.
Why interesting to a deal team
Counsel to Curewell Capital on 2025 investment; critical for understanding CDMO sector dynamics and PE add-on acquisition strategy in pharma services.
Experts connected to this company
- Adam M. WexnerKirkland counsel to Curewell Capital on its 2025 investment
- William S. RichmondKirkland healthcare team advised investor Curewell Capital
AM
Adam M. Wexner
Partner
Kirkland & Ellis LLP
LawyerChicago
He's Kirkland's go-to deal lawyer for pharma-services and CDMO transactions, sitting inside EW Healthcare's and Curewell Capital's live deal pipeline.
WS
William S. Richmond
Partner
Kirkland & Ellis LLP
LawyerWashington
Kirkland healthcare regulatory partner behind Avidity/Novartis, Akero/Novo Nordisk, Amicus/BioMarin and Curewell's CDMO investment — a direct line into live pharma services deal flow.
Sources
- Page titlePressArchived 2025-10-21businesswire.com/news/home/20251021135557/en/Wilmington-PharmaTech-Continues-Expansion-with-Significant-Investment-from-Curewell-Capital
- No name matchPressBot-blockedbusinesswire.com/news/home/20260323322230/en/Wilmington-PharmaTech-Launches-$50-Million-Expansion-to-Double-U.S.-Small-Molecule-API-Manufacturing-Capacity-in-Delaware
- Page titlePrimarywilmingtonpharmatech.com
Strongest evidencePage title3 public sourcesHow the grades work